Share on StockTwits

Echo Therapeutics (NASDAQ:ECTE) major shareholder Mark Nordlicht bought 65,739 shares of the stock in a transaction that occurred on Monday, June 30th. The shares were purchased at an average cost of $2.20 per share, for a total transaction of $144,625.80. The acquisition was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Shares of Echo Therapeutics (NASDAQ:ECTE) traded down 0.44% during mid-day trading on Tuesday, hitting $2.25. The stock had a trading volume of 31,731 shares. Echo Therapeutics has a one year low of $1.53 and a one year high of $4.91. The stock has a 50-day moving average of $1.9 and a 200-day moving average of $2.89. The company’s market cap is $27.0 million.

Echo Therapeutics (NASDAQ:ECTE) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.08. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. On average, analysts predict that Echo Therapeutics will post $-0.90 earnings per share for the current fiscal year.

Separately, analysts at Feltl & Co. downgraded shares of Echo Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 12th.

Echo Therapeutics, Inc (NASDAQ:ECTE) is a medical device and specialty pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.